Narges Ansari
1 , Mansour Salesi
2* 1 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Collapsing glomerulopathy is a rare but severe form of glomerular injury that can be accompanying by SLE (systemic lupus erythematosus). The pathogenesis of collapsing glomerulopathy in lupus is not well understood, and the treatment options are limited. The treatment of collapsing glomerulopathy in lupus is challenging. Immunosuppressive therapy with corticosteroids and cytotoxic agents is the mainstay of treatment. However, the response to therapy is often poor, and many patients progress to end-stage renal disease despite treatment. The use of newer agents such as rituximab and belimumab may offer additional options for the treatment of collapsing glomerulopathy in lupus. Further studies are required to better detect the underlying mechanisms of collapsing glomerulopathy in lupus and to develop more effective therapies for this condition.
Implication for health policy/practice/research/medical education:
Collapsing glomerulopathy in lupus nephritis is associated with poor prognosis and rapid progression to end-stage renal disease.
Please cite this paper as: Ansari N, Salesi M. Lupus-associated collapsing glomerulopathy; a current data. J Nephropathol. 2024;13(4):e21528. DOI: 10.34172/jnp.2024.21528.